{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:42:41Z","timestamp":1793310161546,"version":"4.5.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"\n Importance<\/jats:title>\n Chronic pruritus, defined as itch experienced for 6 weeks or longer, affects approximately 22% of people in their lifetime. Approximately 1% of physician visits are for the chief concern of chronic pruritus. Chronic pruritus is associated with adverse outcomes, including impaired sleep and reduced quality of life.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n Chronic pruritus can be categorized by etiology into inflammatory, neuropathic, or a combination of inflammatory and neuropathic pruritus. Chronic pruritus is due to inflammation in approximately 60% of patients and may be caused by eczema, psoriasis, or seborrheic dermatitis. Chronic pruritus is due to a neuropathic or mixed etiology in approximately 25% of patients. Neuropathic causes of chronic pruritus include postherpetic neuralgia and notalgia paresthetica and are typically due to localized or generalized nerve dysregulation. Approximately 15% of people with chronic pruritus have other causes including systemic diseases with secondary itch, such as uremic pruritus and cholestatic pruritus, medication-induced pruritus such as pruritus due to immunotherapy, and infectious etiologies such as tinea corporis and scabies. When few primary changes are present, a thorough history, review of symptoms, and laboratory evaluation should be performed, particularly for people with chronic pruritus lasting less than 1 year. Clinicians should consider the following tests: complete blood cell count, complete metabolic panel, and thyroid function testing to evaluate for hematologic malignancy, liver disease, kidney disease, or thyroid disease. First-line treatment for inflammatory chronic pruritus includes topical anti-inflammatory therapies such as hydrocortisone (2.5%), triamcinolone (0.1%), or tacrolimus ointment. Approximately 10% of patients do not respond to topical therapies. In these patients, referral to dermatology and systemic oral or injectable treatments such as dupilumab or methotrexate may be considered. When no underlying systemic disease associated with pruritus is identified, patients are likely to have neuropathic chronic pruritus or mixed etiology such as chronic pruritus of unknown origin. In these patients, neuropathic topical treatments such as menthol, pramoxine, or lidocaine can be used either alone or in combination with immunomodulatory agents such as topical steroids. Other effective therapies for neuropathic pruritus include gabapentin, antidepressants such as sertraline or doxepin, or opioid receptor agonist\/antagonists such as naltrexone or butorphanol.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Chronic pruritus can adversely affect quality of life and can be categorized into inflammatory, neuropathic, or a combined etiology. First-line therapies are topical steroids for inflammatory causes, such as hydrocortisone (2.5%) or triamcinolone (0.1%); topical neuropathic agents for neuropathic causes, such as menthol or pramoxine; and combinations of these therapies for mixed etiologies of chronic pruritus.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2024.4899","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:01:01Z","timestamp":1716980461000},"page":"2114","source":"Crossref","is-referenced-by-count":131,"title":["Chronic Pruritus"],"prefix":"10.1001","volume":"331","author":[{"given":"Daniel C.","family":"Butler","sequence":"first","affiliation":[{"name":"University of Arizona College of Medicine, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Elmariah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chisolm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University, Grady Memorial Hospital, Atlanta, Georgia"},{"name":"Regional Telehealth Service, Veterans Affairs Veterans Integrated Service Network 7 Southeast Network, Duluth, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mollanazar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Miami Itch Center, Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jrv240009r1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaad.2013.05.029","article-title":"Itch as a patient-reported symptom in ambulatory care visits in the United States.","volume":"69","author":"Shive","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jrv240009r2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.1087-0024.2003.09111.x","article-title":"Self-reported skin morbidity among adults: associations with quality of life and general health in a Norwegian survey.","volume":"9","author":"Dalgard","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"jrv240009r3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730.","volume":"221","author":"St\u00e4nder","year":"2010","journal-title":"Dermatology"},{"issue":"6","key":"jrv240009r4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamadermatol.2013.7696","article-title":"Factors mediating the impact of chronic pruritus on quality of life.","volume":"150","author":"Carr","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"jrv240009r5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study.","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"jrv240009r6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ijd.2006.45.issue-6","article-title":"The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients.","volume":"45","author":"Yal\u00e7in","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2","key":"jrv240009r7","first-page":"77","article-title":"Notalgia paresthetica associated with cervical spinal stenosis and cervicothoracic disk disease at C4 through C7.","volume":"85","author":"Alai","year":"2010","journal-title":"Cutis"},{"issue":"4","key":"jrv240009r8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2021.09.014","article-title":"IL-33 signaling in sensory neurons promotes dry skin itch.","volume":"149","author":"Trier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"jrv240009r9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch.","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"jrv240009r10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/exd.v28.12","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice.","volume":"28","author":"Campion","year":"2019","journal-title":"Exp Dermatol"},{"key":"jrv240009r11","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1258823","article-title":"Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli.","volume":"16","author":"Mack","year":"2023","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"jrv240009r12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch.","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"3","key":"jrv240009r13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch.","volume":"100","author":"Cevikbas","year":"2020","journal-title":"Physiol Rev"},{"issue":"3","key":"jrv240009r14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","article-title":"Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb.","volume":"150","author":"Miron","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"jrv240009r15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"jrv240009r16","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac140.038","article-title":"344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2).","volume":"188","author":"Yosipovitch","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"jrv240009r17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus.","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv240009r18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis.","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"jrv240009r19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch.","volume":"8","author":"Meixiong","year":"2019","journal-title":"Elife"},{"issue":"1","key":"jrv240009r20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.201708092","article-title":"Senescence and aging: causes, consequences, and therapeutic avenues.","volume":"217","author":"McHugh","year":"2018","journal-title":"J Cell Biol"},{"issue":"6","key":"jrv240009r21","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"jrv240009r22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis.","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv240009r23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jaad.2019.06.038","article-title":"Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment.","volume":"81","author":"Kim","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"jrv240009r24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective.","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"jrv240009r25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.615334","article-title":"Clinical characteristics of itch in renal transplant recipients.","volume":"7","author":"Krajewski","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"jrv240009r26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2340\/00015555-0650","article-title":"Drug-induced pruritus: a review.","volume":"89","author":"Reich","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"jrv240009r27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/ph16101500","article-title":"Comprehensive study of drug-induced pruritus based on adverse drug reaction report database.","volume":"16","author":"Nakao","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"jrv240009r28","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI guideline on chronic prurigo including prurigo nodularis.","volume":"5","author":"St\u00e4nder","year":"2020","journal-title":"Itch (Phila)"},{"issue":"7","key":"jrv240009r29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamadermatol.2022.1562","article-title":"Risk of hematologic cancer in patients with undifferentiated pruritus.","volume":"158","author":"Deng","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"jrv240009r30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2018.08.044","article-title":"Association between itch and cancer in 16,925 patients with pruritus: experience at a tertiary care center.","volume":"80","author":"Larson","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv240009r31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.v60.1","article-title":"Pruritus in cholestasis: facts and fiction.","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"jrv240009r32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jdv.2006.20.issue-6","article-title":"An epidemiology study of patients with uremic pruritus.","volume":"20","author":"Mistik","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"jrv240009r33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/DAD.0000000000001902","article-title":"Chronic itch of unknown origin is associated with an enhanced Th2 skin immune profile.","volume":"43","author":"Dehner","year":"2021","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"jrv240009r34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.v185.3","article-title":"Immunological eruptions of ageing: reframing chronic pruritic rashes in older adults.","volume":"185","author":"Abel","year":"2021","journal-title":"Br J Dermatol"},{"key":"jrv240009r35","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4238139","article-title":"Prevalence and relevance of pruritus in pregnancy.","volume":"2017","author":"Szczech","year":"2017","journal-title":"Biomed Res Int"},{"key":"jrv240009r36","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.8488","article-title":"Psychopathology associated with chronic pruritus: a systematic review.","volume":"103","author":"Ferreira","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"jrv240009r37","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches.","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"jrv240009r38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/tcrm.2006.2.issue-2","article-title":"Treatment of pruritic diseases with topical calcineurin inhibitors.","volume":"2","author":"St\u00e4nder","year":"2006","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"jrv240009r39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5021\/ad.2012.24.2.144","article-title":"A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis.","volume":"24","author":"Takeuchi","year":"2012","journal-title":"Ann Dermatol"},{"issue":"2","key":"jrv240009r40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2022.03.012","article-title":"Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: a case series.","volume":"87","author":"Ju","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"jrv240009r41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/issn.1421-5721","article-title":"Itch management in the elderly.","volume":"50","author":"Leslie","year":"2016","journal-title":"Curr Probl Dermatol"},{"issue":"8","key":"jrv240009r42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jamadermatol.2021.2010","article-title":"Association of neuropathic itch with patients\u2019 quality of life.","volume":"157","author":"Lipman","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"9","key":"jrv240009r43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5483\/BMBRep.2016.49.9.108","article-title":"The peripheral and central mechanisms underlying itch.","volume":"49","author":"Lee","year":"2016","journal-title":"BMB Rep"},{"issue":"3","key":"jrv240009r44","first-page":"243","article-title":"Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream.","volume":"16","author":"Zirwas","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"jrv240009r45","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/ijms24010420","article-title":"Transient receptor potential channels and itch.","volume":"24","author":"Mahmoud","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"jrv240009r46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability.","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"jrv240009r47","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/ijd.v59.8","article-title":"A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.","volume":"59","author":"Aquino","year":"2020","journal-title":"Int J Dermatol"},{"issue":"12","key":"jrv240009r48","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1001\/archderm.135.12.1522","article-title":"An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis.","volume":"135","author":"Klein","year":"1999","journal-title":"Arch Dermatol"},{"issue":"10","key":"jrv240009r49","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00198-018-4564-z","article-title":"Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis.","volume":"29","author":"Cho","year":"2018","journal-title":"Osteoporos Int"},{"issue":"3","key":"jrv240009r50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus.","volume":"75","author":"Matsuda","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"jrv240009r51","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: a systematic review.","volume":"77","author":"Kouwenhoven","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jrv240009r52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-023-03212-3","article-title":"The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial.","volume":"24","author":"Elsayed","year":"2023","journal-title":"BMC Nephrol"},{"issue":"3","key":"jrv240009r53","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/(ISSN)1527-3350","article-title":"Sertraline as a first-line treatment for cholestatic pruritus.","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"jrv240009r54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1080\/09546634.2018.1456639","article-title":"Selective serotonin reuptake inhibitors for the treatment of chronic pruritus.","volume":"29","author":"Boozalis","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"jrv240009r55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/medicines6030073","article-title":"Mirtazapine for the treatment of chronic pruritus.","volume":"6","author":"Khanna","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"9","key":"jrv240009r56","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamadermatol.2023.1772","article-title":"Ketamine infusions for treatment-resistant neuropathic pruritus.","volume":"159","author":"Kwatra","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"jrv240009r57","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/exd.v31.12","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: peripheral and central itch circuits.","volume":"31","author":"Kim","year":"2022","journal-title":"Exp Dermatol"},{"issue":"6","key":"jrv240009r58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa2210699","article-title":"Phase 2 trial of difelikefalin in notalgia paresthetica.","volume":"388","author":"Kim","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv240009r59","doi-asserted-by":"publisher","first-page":"e2210339","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial.","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jrv240009r60","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3360","article-title":"Methotrexate in the treatment of chronic itch in the geriatric population.","volume":"100","author":"Kursewicz","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"jrv240009r61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archderm.139.2.223","article-title":"Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis.","volume":"139","author":"Legat","year":"2003","journal-title":"Arch Dermatol"},{"issue":"9","key":"jrv240009r62","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/sj.ki.5000251","article-title":"Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients.","volume":"69","author":"Narita","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"jrv240009r63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/medicines6030072","article-title":"Chronic pruritus responding to dupilumab\u2014a case series.","volume":"6","author":"Zhai","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"5","key":"jrv240009r64","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"jrv240009r65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40257-022-00738-4","article-title":"Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial.","volume":"24","author":"St\u00e4nder","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"jrv240009r66","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1079323","article-title":"Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: a systematic literature review and meta-analysis.","volume":"9","author":"Rodriguez-Le Roy","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"jrv240009r67","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials.","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"jrv240009r68","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"6S1","key":"jrv240009r69","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/DER.0000000000000962","article-title":"Evaluation of a comprehensive web-based educational program for nursing staff on atopic eczema and its management.","volume":"33","author":"Bekhash","year":"2022","journal-title":"Dermatitis"},{"issue":"2","key":"jrv240009r70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2340\/00015555-2177","article-title":"Psychological interventions in the treatment of chronic itch.","volume":"96","author":"Schut","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"jrv240009r71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/exd.v31.3","article-title":"Electrical neurostimulation for the treatment of chronic pruritus: a systematic review.","volume":"31","author":"Badwy","year":"2022","journal-title":"Exp Dermatol"},{"key":"jrv240009r72","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.786892","article-title":"Acupuncture for the treatment of itch: peripheral and central mechanisms.","volume":"15","author":"Tang","year":"2022","journal-title":"Front Neurosci"},{"issue":"9","key":"jrv240009r73","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3892","article-title":"Chronic pruritus of unknown origin: clinical profile and disease-related burden.","volume":"101","author":"Pereira","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"jrv240009r74","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1097\/j.pain.0000000000001678","article-title":"Itch sensitization? a systematic review of studies using quantitative sensory testing in patients with chronic itch.","volume":"160","author":"van Laarhoven","year":"2019","journal-title":"Pain"},{"issue":"6","key":"jrv240009r75","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","article-title":"Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials.","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"jrv240009r76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2019.06.043","article-title":"Validity and reliability of itch assessment scales for chronic pruritus in adults: a prospective multicenter study.","volume":"82","author":"Jang","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jrv240009r77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2021.09.062","article-title":"The association of chronic pruritus with patients\u2019 quality of life: a cross-sectional study.","volume":"86","author":"Lipman","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv240009r78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000437206","article-title":"Health-related quality of life in chronic pruritus: an analysis related to disease etiology, clinical skin conditions and itch intensity.","volume":"231","author":"Warlich","year":"2015","journal-title":"Dermatology"},{"issue":"3","key":"jrv240009r79","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaad.2019.06.031","article-title":"Symptoms of depression and anxiety are associated with poorer functional outcomes in chronic pruritus.","volume":"85","author":"Cole","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jrv240009r80","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jid.2019.05.034","article-title":"Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries.","volume":"140","author":"Dalgard","year":"2020","journal-title":"J Invest Dermatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2819296\/jama_butler_2024_rv_240009_1718317231.93479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:06:02Z","timestamp":1719313562000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2819296"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":80,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.4899","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}